Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 54
- Registration Number
- NCT05868226
- Locations
- 🇺🇸
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 41
- Registration Number
- NCT05744375
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 402
- Registration Number
- NCT05704829
- Locations
- 🇩🇪
Universitätsklinikum Essen, Brustzentrum, Essen, Germany
🇩🇪Breast Center of the University of Munich (LMU) Universitätsfrauenklinik, Munich, Bavaria, Germany
🇩🇪Rotkreuz Klinikum München, Muenchen, Bayern, Germany
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 198
- Registration Number
- NCT05650879
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT05633979
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 150
- Registration Number
- NCT05594082
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Brown University
- Target Recruit Count
- 25
- Registration Number
- NCT05480384
- Locations
- 🇺🇸
Weill Cornell Medicine/New York-Presbyterian, New York, New York, United States
🇺🇸Lifespan Cancer Institute, Providence, Rhode Island, United States
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 256
- Registration Number
- NCT05458401
- Locations
- 🇮🇹
Institute Oncology Veneto, Padua, Italy
🇮🇹Fondazione Policlinico Univeritario Agostino Gemeli, Rome, Italy
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.